(NASDAQ: INDV) Indivior Pharmaceuticals's forecast annual revenue growth rate of 2.16% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Indivior Pharmaceuticals's revenue in 2026 is $1,291,000,000.On average, 8 Wall Street analysts forecast INDV's revenue for 2026 to be $151,792,962,210, with the lowest INDV revenue forecast at $134,480,029,974, and the highest INDV revenue forecast at $163,985,168,010. On average, 8 Wall Street analysts forecast INDV's revenue for 2027 to be $158,498,675,400, with the lowest INDV revenue forecast at $141,551,509,338, and the highest INDV revenue forecast at $171,300,491,490.
In 2028, INDV is forecast to generate $168,496,284,156 in revenue, with the lowest revenue forecast at $155,938,312,182 and the highest revenue forecast at $183,736,541,406.